ECOG-ACRIN A Randomized Phase II Trial for High-Risk Multiple Myeloma that is Refractory or in First Relapse with Daratumumab, Teclistamab (DT) versus Daratumumab, Pomalidomide, dexamethasone (DPd) or Daratumumab, Carfilzomib, dexamethasone (DKd) Adult CIRB - Late Phase Emphasis Active Available to Open